Day: June 23, 2020

AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101.This study is designed to evaluate the safety, tolerability, and effectiveness of OT-101 when used in combination with standard of care (SoC) in hospitalized COVID-19 patients.  OT-101 is a wide spectrum anti-viral agent with demonstrated activity against SARS-CoV-2 in the nanomolar range comparable to remdesivir, however, with higher safety index. By targeting the host protein, TGF-β, OT-101 avoids resistance mutations which could render vaccine and/or therapeutics against viral protein(s) ineffective.Chris Giordano, President, IQVIA Biotech, stated: “The COVID-19 pandemic is the greatest health...

TORONTO, June 23, 2020 (GLOBE NEWSWIRE) — Caldas Gold Corp. (TSX-V: CGC; OTCQX: ALLXF) announced today that its common shares will commence trading today on the OTCQX® Best Market in the United States under the symbol “ALLXF”. Caldas Gold’s common shares will continue to trade on the Toronto Stock Venture Exchange under the symbol “CGC”.Serafino Iacono, Chairman and CEO of Caldas Gold, commented, “The OTCQX platform will provide our growing shareholder base with increased visibility and transparency by facilitating trading of our common shares in the United States. While our primary listing is on the TSX-V in Canada, we appreciate that some investors prefer to trade in U.S. dollars on the OTCQX market.”U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.About Caldas...

CALGARY, Alberta, June 23, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Mr. Anthony J. Giovinazzo will become a Special Advisor to the CEO and the Board of Directors.Mr. Giovinazzo’s mandate will be to advise Dr. Allen Davidoff, CEO and the Board of Directors on strategic and capital markets aspects of the Company’s activities and to aid in the advancement of our two key programs.XORTX’s two key programs in autosomal dominant polycystic kidney disease (ADPKD) and the treatment of acute kidney injury due to coronavirus COVID-19 infection are advancing toward clinical trial initiation. In parallel with this progress, critical activities...

NEW HAVEN, Conn., June 23, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced the appointment of Reina Benabou, M.D., Ph.D., as Senior Vice President and Chief Development Officer (CDO). Dr. Benabou has over 20 years of experience in directing drug development programs and implementing medical affairs strategies for product commercialization in neurology and psychiatry.“We couldn’t be more pleased to welcome Reina to BTI, as her addition will significantly strengthen our leadership structure,” commented Vimal Mehta, Ph.D., Chief Executive Officer of BTI. “Reina’s expertise in bringing neuroscience products to market will be an important...

SAN FRANCISCO, June 23, 2020 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with acute coronavirus 2019 (COVID-19) infection. This multicenter trial is being conducted in the U.S. and will enroll approximately 130 patients with COVID-19.The primary objective of this study is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 infection, and patients will be randomized to treatment with pamrevlumab or standard of care in a 1:1 ratio. The primary efficacy assessment is the proportion of hospitalized COVID-19 patients who have not received mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) and remain alive at...

ROUYN-NORANDA, Quebec, June 23, 2020 (GLOBE NEWSWIRE) — Radisson Mining Resources Inc. (TSX-V: RDS, OTC: RMRDF): (“Radisson” or the “Company”) is pleased to announce the addition of one diamond drill rig to the O’Brien project, bringing the total drills on site to 3 rigs. This additional drill rig was mobilized on June 19, 2020 and has been set up on drilling a pilot hole on the Lower F Zone. The ongoing drill program, expanded to 60,000 metres in February 2020, represents the company’s first exploration program to test targets defined by the new litho-structural model (released February 2019).The new drill rig is testing the western extension of the enrichment vector drilled down to a depth of 950 m on the Lower 36E Zone. Current resources are largely limited to 600 m vertical depth, deeper drill holes including OB-19-92W2b...

ROUYN-NORANDA, Québec, 23 juin 2020 (GLOBE NEWSWIRE) — Ressources minières Radisson Inc. (TSXV: RDS) (« Radisson » ou la « Société ») est heureuse d’annoncer d’annoncer l’ajout d’une foreuse au diamant au projet aurifère O’Brien, portant le total à 3 foreuses. La foreuse supplémentaire fût mobilisée le 19 juin, 2020 et fore actuellement un trou pilote sur le secteur Lower F. Le programme de forage en cours, augmenté à 60 000 mètres en février 2020, représente le premier programme d’exploration testant les cibles établies à l’aide du nouveau modèle litho-structural (publié en février 2019).La foreuse supplémentaire cible à l’ouest du vecteur d’enrichissement foré jusqu’à une profondeur de 950 m sur la Zone Lower 36E qui demeure un secteur à haute priorité pour l’expansion des ressources alors qu’elles  sont largement...

VANCOUVER, British Columbia, June 23, 2020 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that its Verdélite Sciences subsidiary in St. Eustache, Québec, has launched its new Souvenir cannabis brand in the province. The Souvenir product line initially consists of select dried flower products from two Emerald cultivars, Grapefruit GG4 and Chemdog. The first shipments have been made to the SQDC, Québec’s cannabis distribution board, and will be distributed through SQDC retail and online stores.Souvenir is focused on bringing unique offerings to the Québec market at a competitive price point. Artisanal care and freshness are implicit in Verdélite’s cultivation, harvesting, and production philosophy. Every batch of dried flower product is hand harvested, hang dried and dry trimmed,...